All In Biotech

Drug Trial Radar · NCT00190593

Raloxifene Use for The Heart

Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events

Last checked: Nov 19, 2026Latest source record: Jan 26, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,000

Actual

Start

Jun 1998

Primary completion

Not stated

Study completion Nov 2005

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Prevention
Who can join
Female only, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

Conditions

  • Cardiovascular Diseases
  • Breast Neoplasms

Interventions

  • raloxifeneDrug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.
  2. Time to first occurrence of invasive breast cancer after an expected 5 to 7.5 years of follow-up.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.